NEW YORK (GenomeWeb News) – Bristol-Myers Squibb and Meso Scale Discovery today announced a deal to develop assays for use in Alzheimer's disease research.
The assays, which will measure biomarkers in cerebrospinal fluid, will be based on the Meso Scale Discovery Multi-Array technology platform. The technology consists of proprietary patterned arrays and electrochemiluminescence detection and enables "large number of measurements with exceptional sensitivity, wide dynamic range, and convenience," according to Meso Scale Discovery, a division of Meso Scale Diagnostics.
Meso Scale Discovery, based in Gaithersburg, Md., plans to commercialize the assays for Alzheimer's research and drug development in the second quarter.
"These assays could provide the Alzheimer's disease research community with an important tool to help advance understanding of this complex and devastating disease and may lead to advances in the diagnosis and treatment of Alzheimer's disease," Jane Tiller, vice president of global clinical research for Bristol-Myers Squibb, said in a statement.
Financial and other terms were not disclosed.